Bookmark Kaumudi Online  Bookmark this site  Editor@Kaumudi  |  Marketing  Print Advt rates  |  Calendar 2018        Go!    
 
 
September 24, Monday 2018 10:51 AM       

       HEADLINES: Three killed in two accidents at Ernakulam                                              PM Modi to launch Ayushman Bharat today                                              Hollande's statement, Rahul's tweet "orchestrated": Jaitley                                              PM to inaugurate Sikkim's first airport Monday                                              Pak man sings Indian national anthem at Indo-Pak match                                              Japanese supply ship heads to space station after delays                                              Russia warns US it is 'playing with fire' with sanctions                                              Pak PM Imran hits out at India, calls its response "arrogant" for cancelling talks                                              Gavaskar impressed with Rohit Sharma's captaincy                                              Hasan, Asghar, Rashid fined 15 per cent of their match fees                                              Kaumudi Facebook
       SCI&TECH Next Article: Threat of asteroid impact looming over Earth: experts  
       New drug to treat blood cancer developed
 
         Posted on :19:38:19 Jun 10, 2017
   
A A
       Last edited on:19:38:19 Jun 10, 2017
         Tags: New drug, blood cancer
 
NEW YORK: A new drug for blood cancer that may provide better treatment alone or combined with chemotherapy has been developed by a team led by an Indian-origin scientist.
 
Acute lymphoblastic leukemia or ALL can affect both children and adults.
 
Scientists have found up to 30 per cent of adult ALL patients have what is called a Philadelphia chromosome, where two segments of chromosomes have aberrantly fused together. The ALL cancer cells containing the Philadelphia chromosome are addicted to repairing DNA.
 
"Repairing DNA may sound like a good thing when you are talking about healthy cells. But in this case it is a bad thing. When you treat these leukemia cells with chemotherapy, you want DNA damage to accumulate so the cancer cells will die," said Srividya Bhaskara, a post doctoral at University of Utah in the US.
 
"However, because the Philadelphia chromosome continually causes repair, these cells do not retain enough DNA damage to die. Essentially they resist any kind of drug you use on them. So we had to find a new way to overcome this DNA repair addiction," she said.
 
Researchers found that the Philadelphia chromosome promotes repair through numerous proteins. But putting together a cocktail of drugs to inhibit them all would likely be too toxic and affect normal cells.
 
Bhaskara focused on two specific proteins she found were directly involved in DNA repair, called histone deacetylases (HDAC) 1 and 2. She then collaborated with a company to make a drug that inhibits HDAC1,2 activity.
 
After a comprehensive analysis of how the drug worked, Bhaskara tested the HDAC1,2 inhibitor in patient samples and mice and saw encouraging results, either alone or in combination with a chemotherapy drug called doxorubicin.
 
Doxorubicin is one of the components of the chemotherapy cocktail regimen currently used for Philadelphia chromosome-positive ALL patients.
 
Researchers found that the drugs broke down the central hub of DNA repair, and the HDAC1,2 inhibitor actually reduced different repair protein functions.
 
"The treated mice did not get sick from the drug, and we did not see any apparent toxic side-effects in them. And when the drug was combined with a low concentration of doxorubicin, it had additional therapeutic benefits," Bhaskara said.
 
"We actually show in the patient-derived mouse models that using the combination of drugs, or HDAC1,2 inhibitor alone, is sufficient to decrease the leukemia load," she said.
 
Leukemia is a white blood cell disease where the body produces too many white and not enough red blood cells.
 
When the mice in this study were treated with the HDAC1,2 inhibitor or the HDAC1,2/doxorubicin combination, their bone marrow started turning from pale to red, indicating the white blood cells were being replaced with red blood cells, researchers said.
 
"We completely nailed down how the HDAC1,2 inhibitor affects DNA repair. This is so important, not just for this cancer, but any cancer that is repair-addicted. We know there is a specific type of lymphoma that is also repair-addicted," Bhaskara said.
 
The study was published in the journal Leukemia.
A A
       SCI&TECH
Next Article: Threat of asteroid impact looming over Earth: experts
 
 
SCI&TECH HEADLINES
Pluto should be reclassified as a planet, reveals study  
Shared responsibility essential for conserving migratory species  
Microsoft releases Speech Corpus for three Indian languages  
Facebook likely to run on 100% renewable energy by 2020  
Can brain suppress the act of revenge?  
Kerala techies launch portal to facilitate relief measures  
Here's what you may not know about H2O  
Alexa will tell you when it has done its homework  
Students recreate horrific atomic bombings of Hiroshima using VR technology  
Study discovers compounds that can reverse cell ageing  
Online interactive courses on AI in trading, first time on internet  
Apple to fix devices damaged by Japan's floods for free  
IT industry should focus on developing new technologies  
Skype adds read receipts to chats  
Mobile app for replacement of transformers in Raj  
Kashmiri students make solar boat for Dal Lake  
NASA prepares to fly probe into Sun's scorching atmosphere  
Yoga helps against non-communicable diseases: WHO  
Spironolactone can help prevent acne: Study  
Older Amazonian forests help regulate global climate  
Goal conflict linked to depressive symptoms  
A new world: Top 10 new species for 2018  
Beat the risk of frailty with healthy heart  
Twitter to hide trolls that hurl abuse: Twitter CEO  
Fortnite is finally coming to Android  
 
Do you agree with Rahul's allegation against Modi over Rafale deal?
yes
 
no
 
no opinion
 
 
 
Home Kerala India World Business Sports Sci&Tech Education Automobile CityNews Movies Environment Letters 
© Copyright keralakaumudi Online 2011  |  Reproduction in whole or in part without written permission is prohibited.
Head Office Address: Kaumudi Buildings, Pettah P.O, Trivandrum - 695024, India.
Online queries talk to Deepu Sasidharan, + 91 98472 38959 or Email deepu[at]kaumudi.com
Customer Service -Advertisement Disclaimer Statement   |  Copyright Policy